Compare · ITGR vs NXL
ITGR vs NXL
Side-by-side comparison of Integer Holdings Corporation (ITGR) and Nexalin Technology Inc. (NXL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITGR and NXL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- ITGR is the larger of the two at $3.24B, about 308.3x NXL ($10.5M).
- Over the past year, ITGR is down 14.5% and NXL is down 60.2% - ITGR leads by 45.7 points.
- ITGR has been more active in the news (5 items in the past 4 weeks vs 2 for NXL).
- ITGR has more recent analyst coverage (23 ratings vs 0 for NXL).
- Company
- Integer Holdings Corporation
- Nexalin Technology Inc.
- Price
- $95.31-4.40%
- $0.48+6.58%
- Market cap
- $3.24B
- $10.5M
- 1M return
- +4.58%
- +21.63%
- 1Y return
- -14.54%
- -60.21%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 5
- 2
- Recent ratings
- 23
- 0
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Latest ITGR
- SEC Form 3 filed by new insider Metcalf Milo Stephen Ii
- SEC Form 4 filed by US - EVP, Operations Metcalf Milo Stephen Ii
- Integer Announces Conference Call to Discuss Second Quarter 2026 Results
- Chief Human Resources Officer Thor Kirk K converted options into 6,120 shares and covered exercise/tax liability with 2,409 shares, increasing direct ownership by 11% to 38,693 units (SEC Form 4)
- SEC Form 4 filed by President, Glob Ops & Manu Tec Harris John A
- Integer Holdings Corporation filed SEC Form 8-K: Leadership Update
- Integer to Participate in Truist Securities 2026 MedTech Conference on June 16
- Director Maxwell Martin C was granted 1,967 shares, increasing direct ownership by 9% to 25,106 units (SEC Form 4)
- SEC Form 4 filed by Director Hinrichs James F.
- Director Coyle Michael J was granted 1,967 shares, increasing direct ownership by 145% to 3,322 units (SEC Form 4)
Latest NXL
- SEC Form DEF 14A filed by Nexalin Technology Inc.
- SEC Form PRE 14A filed by Nexalin Technology Inc.
- Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
- Nexalin Technology Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
- Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
- Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
- Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial